Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23203467 | 0.86 | MTNR1A (0.46) | SLC22A12MTNR1AHDAC6HDAC1HDAC4 | |
| SCHEMBL23202566 | 0.81 | HDAC6 (0.43) | HDAC6HDAC1HDAC4HDAC10HDAC8 | |
| SCHEMBL29779623 | 0.81 | HDAC3 (0.41) | HDAC6HDAC1HDAC4HDAC8HDAC3 | |
| SCHEMBL23167369 | 0.81 | HDAC3 (0.41) | HDAC6HDAC1HDAC4HDAC8HDAC3 | |
| SCHEMBL23201965 | 0.78 | HDAC6 (0.52) | HDAC6HDAC1HDAC4HDAC10HDAC8 | |
| SCHEMBL17165055 | 0.78 | HDAC6 (0.64) | MTNR1AHDAC6HDAC1HDAC4HDAC10 | |
| SCHEMBL23202570 | 0.76 | PTGDR2 (0.44) | HDAC6HDAC1HDAC4HDAC10HDAC8 | |
| SCHEMBL23167484 | 0.72 | FGFR1 (0.45) | HDAC3HDAC2 | |
| SCHEMBL23167363 | 0.71 | FGFR1 (0.48) | HDAC1HDAC3HDAC2 | |
| SCHEMBL23167492 | 0.70 | FGFR1 (0.48) | HDAC6HDAC8HDAC3HDAC2HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381148-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | TENAYA THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230381148-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | TENAYA THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230123856-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | TENAYA THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| WO-2021067859-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | TENAYA THERAPEUTICS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381148-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | HDAC6, HDAC1, HDAC2 | SLC22A12 1041/4885MTNR1A 1685/4885HDAC6 1/4885 |
| US-20230123856-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | SLC28A1, SLC5A1, SLC9A5 | SLC22A12 175/4885MTNR1A 1528/4885HDAC6 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.